MedTrace Logo

An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease

NCT04352491 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 347

Last updated 2020-06-17

No results posted yet for this study

Summary

The current outbreak of COVID-19 pandemic has been marked by severe psychological problems. People around the world experienced a similarly frightening public health emergency, on a global scale, with the spread of this corona infection. (1) Studies of the Severe Acute Respiratory Syndrome (SARS) outbreaks that occurred in Canada, Taiwan, and Hong Kong found that the enormous emotional burden carried by those health care workers who were on the front lines of the battle against the disease led to psychological morbidity like anxiety, stress and even further leads to Post traumatic stress disorder. The initial phase of the COVID-19 outbreak in China in 2020 also reported more than half of the respondents rated the psychological impact as moderate-to-severe, and about one-third reported moderate-to-severe anxiety in general population.(2)

\- The chances of Fear, anxiety and stress are even higher in Individuals with preexisting liver disease as they have restriction of services for getting treatment. Moreover, they can have the following additional issues:

* Fear of severe form of Corona present (as presented in most of the media and research)
* Fear of dying
* Added uncertainty
* Family members also worried

Conditions

  • COVID 19

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Institute of Liver and Biliary Sciences, India

    lead OTHER

Principal Investigators

  • Dr Shiv Kumar Sarin, DM · Institute of Liver & Biliary Sciences

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-24
Primary Completion
2020-05-31
Completion
2020-05-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04352491 on ClinicalTrials.gov